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a b s t r a c t
Equine inﬂuenza is a major cause of respiratory infections in horses and causes widespread epidemics, despite
the availability of commercial vaccines. Antigenic drift within the haemagglutinin (HA) glycoprotein is thought
to play a part in vaccination breakdown. Here, we carried out a detailed investigation of the 1989 UK outbreak,
using reverse genetics and site-directed mutagenesis, to determine the individual contribution of amino acid
substitutions within HA. Mutations at positions 159, 189 and 227 all altered antigenicity, as measured by
haemagglutination-inhibition assays. We also compared HA sequences for epidemic and vaccine strains from
four epidemics and found that at least 8 amino acid differences were present, affectingmultiple antigenic sites.
Substitutions within antigenic site B and at least one other were associated with each outbreak, we also
identiﬁed changes in loop regions close to antigenic sites that have not previously been highlighted for human
H3 inﬂuenza viruses.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
It is well known that mammalian inﬂuenza viruses undergo
antigenic drift through acquisition of amino acid substitutions within
the viral glycoproteins haemagglutinin (HA) and neuraminidase (NA),
leading to the occurrence of disease epidemics. For this reason, vaccine
strains to inﬂuenza viruses eventually become ineffective, unless they
are updated regularly. The HA1 domain appears to be under the most
selective pressure, consistent with its role in induction of neutralising
antibodies (Nelson and Holmes, 2007). Substitutions in human H3
viruses have been associated with changes in charge, acquisition of
glycosylation sites and also alteration of receptor binding avidity
(Blackburne et al., 2008; Kobayashi and Suzuki, 2012; Lin et al.,
2012). Changes in HA are often accompanied by substitutions in NA
and it is believed that the activity of HA and NA should be balanced
(Mitnaul et al., 2000; Kaverin et al., 1998; Baigent and McCauley,
2001). The rate of antigenic change differs between inﬂuenza viruses
of different species: human H3N2 viruses appear to drift more rapidly
than either swine H3N2 or equine H3N8 viruses, as assayed by
haemagglutination inhibition (HI) with ferret antisera. This has been
demonstrated by antigenic cartography, which indicated that human
H3N2 viruses underwent multiple ‘cluster jumps’ between 1968 and
2003 (Smith et al., 2004) whereas equine and swine viruses evolved
fewer antigenic clusters over a similar period of time (de Jong et al.,
2007; Lewis et al., 2011).
Inﬂuenza virus of the H3N8 subtype was ﬁrst reported in horses in
1963 and subsequently spread around the world, affecting the UK in
1965 (Rose, 1966). Early reports suggested that equine inﬂuenza virus
(EIV) did not undergo antigenic drift (Burrows et al., 1981), however it
is now clear that the virus acquires mutations in HA that lead to
antigenic drift in much the same way as other inﬂuenza A viruses
(Daniels et al., 1985; Oxburgh et al., 1993; Lewis et al., 2011). Multiple
lineages and sub-lineages have evolved since 1963, including the
divergence of the Eurasian and American viruses of the late 1980s
(Daly et al., 1996), followed by further division of the American lineage
into the Kentucky, Argentinian and Florida clade 1 and 2 (FC1, FC2)
sublineages (Lai et al., 2001; Bryant et al., 2009). Following the initial
pandemic wave in 1965, there have been three further country-wide
outbreaks in the UK in 1979, 1989 and 2003. As a result of the 1979
outbreak, which caused substantial disruption to the racing industry,
mandatory vaccination was introduced for racing Thoroughbreds in
the UK. Other competitive bodies now require vaccination for compe-
tition and rules are laid down by the British Horseracing Authority and
Federation Equestra Internationale (FEI).
In 1989 the UK epidemic affected recently vaccinated and unvacci-
nated animals alike, indicating that the causative strain had undergone
signiﬁcant antigenic drift from the existing vaccine strains (Livesay et
al., 1993; Binns et al., 1993). A similar outbreak occurred in Hong Kong
in 1992, also affecting vaccinated animals (Powell et al., 1995). The
vaccines in use at the time included the EIV prototype H3N8 strain A/
equine/Miami/63, but also more recent pre-divergence strains from
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1979 to 1981. In both the 1989 UK outbreak and the Hong Kong
outbreak the viruses belonged to the Eurasian sub-lineage of EIV (Lai et
al., 1994, 2001). Following the 1989 outbreak in the UK, a surveillance
programmewas established to monitor antigenic drift in EIV and make
recommendations for suitable strains for vaccine use.
In 2003, a large-scale outbreak started in Newmarket, affecting
racing Thoroughbreds despite recent vaccination (Newton et al.,
2006). Again, this was suggestive of antigenic drift, although the
use of simple killed vaccines was also implicated. Vaccines in use
at the time contained Eurasian and American (Kentucky) strains
from the 1990s. A further example of large-scale vaccination bre-
akdown occurred in Japan in 2007, in which vaccines contained
Eurasian and American (Argentinian) strains from 1993 and the
outbreak virus belonged to FC1 (Ito et al., 2008). A consistent
feature of these large scale outbreaks was that commercial
vaccines all contained strains that were at least 10 years older
than the outbreak strain.
Antigenic characterisation of inﬂuenza viruses for the purpose of
vaccine strain selection has been carried out using haemagglutination-
inhibition (HI) assays for human and equine inﬂuenza viruses for
many years (WHO, 2002). Ferret antisera distinguish readily between
EIV strains, whereas equine antisera are typically more cross-reactive
(Hinshaw et al.,1983; Burrows and Denyer, 1982). Current criteria used
for the selection of EIV vaccine strains also include comparison of
amino acid sequences for HA1. More than four amino acid changes in
two or more antigenic sites, based on those mapped for human H3N2
viruses and/or an 8-fold or greater difference in HI titre between
vaccine and circulating virus strains are considered signiﬁcant (Wiley
and Skehel, 1987; Wilson and Cox, 1990). However, the equine H3
molecule remains poorly characterised in this respect and antigenic
sites are typically extrapolated from human H3 viruses (Barbic et al.,
2009; Ito et al., 2008). The ﬁve antigenic sites of human H3 are
thought to represent antibody-binding sites and were originally map-
ped on the basis of sequence variation amongst ﬁeld strains and
generation of escape mutants, selected by passaging viruses in the
presence of monoclonal antibodies or neutralising human antisera
(reviewed by Wiley and Skehel, 1987; Wilson and Cox, 1990). To date,
these methods have not been applied consistently to EIV.
There is no legal requirement for EIV vaccines to be updated and
the process from recommendation of new strains by the OIE to the
appearance of updated commercial vaccines on the market typically
takes several years. It is therefore important that reliable predictive
methods are developed so that suitable recommendations can be
made in a timely fashion. One area of importance is mapping the reg-
ions of EIV H3 that are important for antigenicity, rather than relying
on those mapped for human H3 viruses. In this context, we undertook
a detailed antigenic comparison of vaccine and outbreak strains from
the 1989 UK outbreak. Reverse genetics and site directed mutagenesis
were applied to determine the effect of individual amino acid differ-
ences between the outbreak and vaccine strains, with the aim of
adding to current knowledge of the signiﬁcant amino acid changes for
equine H3. The study was extended by comparison of HA sequences
from outbreak and vaccine strains associated with other known epid-
emics of equine inﬂuenza, using data from 1979, 1989, 2003 and 2007.
Fig. 1. Comparison of vaccine and outbreak EIV strains: 1989 UK outbreak. Derived amino acid sequences for HA1 were aligned for two vaccine strains and three isolates
from the 1989 outbreak in Europe, three contemporary strains from the American (Kentucky) sub-lineage are included for reference. Amino acid substitutions between the
1979 vaccine strains and 1989 ﬁeld strains are outlined in black. Substitutions unique to the Eurasian outbreak strains are indicated by black triangles, two further differences
restricted to the Newmarket/79 vaccine strain are shown by open triangles. Residues are numbered from 1 to 329, starting with serine at the start of the predicted mature
polypeptide for HA1. Genbank accession numbers are: Newmarket/79 – KJ643908, Fontainebleau/79 – KJ643904, Sussex/89 – KJ643906, Yvelines/2136/89 – BAA33940,
Suffolk/89 – KJ643907, Santa Fe/1/85 – ACD85286, Tennessee/5/86 – ACA24656 and Kentucky/692/88 – ACA24579. Source of data and passage history are provided
in Table S1.
A. Woodward et al. / Virology 481 (2015) 187–198188
Results
Comparison of HA1 sequences from 1989 outbreak isolates and
vaccine strains
To identify conserved mutations between the 1989 outbreak str-
ains and vaccine strains in use at the time, two representative vaccine
strains and three outbreak strains from AHT archives were sequenced
and derived amino acid sequences compared (Fig. 1). The vaccine
strains were A/equine/Newmarket/79 (Newmarket/79) and A/equine/
Fontainebleau/79 (Fontainebleau/79), which belong to the Pre-
divergence sub-lineage of EIV; outbreak strains were A/equine/Sus-
sex/89 (Sussex/89), A/equine/Suffolk/89 (Suffolk/89) and A/equine/
Yvelines/89 (Yvelines/89) of the Eurasian sub-lineage. Contemporary
viruses from the 1980s that belonged to the Kentucky sub-lineage (Lai
et al., 2001) were included in the alignment for comparison (Fig. 1).
The latter strains did not cause mass vaccine breakdown in Europe,
unlike those belonging to the Eurasian sub-lineage. Comparison of the
1989 outbreak strains against the vaccine strains identiﬁed 13 amino
acid substitutions that were common to all three 1989 outbreak
strains, distributed throughout the HA1 sequence (Fig. 1). Comparison
of these changes with EIV HA1 sequences available on Genbank to
date indicated that they were common to all of the strains belonging
to the Eurasian sub-lineage, isolated from 1989 onwards (data not
shown). Of these substitutions, four were unique to the Eurasian
lineage [T163I, N189K, K207E and I213V] and three involved changes
in charge: N172K, N189K, K207E. A further two non-conservative
changes were unique to the Newmarket/79 strain comparison: D159N
and P227S whereas the Fontainebleau/79 vaccine had the additional
differences S199L and W222G. Virus isolates belonging to the Ken-
tucky (American) sub-lineage differed from the vaccine strains by up
to 9 amino acids, depending on the isolate, but only N172K involved a
change of charge (Fig. 1).
The locations of individual substitutions between vaccine and
outbreak strains were mapped onto the H3 HA using the A/duck/
Ukraine/63 structure available in PDB [1MLQ, Ha et al. (2003)] and
are shown in the vertical and top views in Fig. 2(A) and (B). This
was the closest structure available to the prototype H3N8 equine
inﬂuenza virus; the mature HA without the signal sequence has
the same number of amino acids as equine H3. Multiple amino
acid differences were located to the top of the HA trimer, forming a
striking ring of substitutions (Fig. 2B). Substitutions also occurred
at other sites within the globular head, both on the surface and
buried within the structure (Fig. 2A).
Antigenic analysis of parental wild type strains from 1989
To select a suitable prototype strain for further analysis, antigenic
characterisation was carried out on low passage isolates from the
1989 outbreak. As described above, these strains belong to the
Eurasian sub-lineage of EIV. The vaccine strains from 1979, included
in commercial vaccines at the time of the outbreak, were also
included to assess the ability of ferret sera to distinguish between
the outbreak and vaccine strains. Since the number of strains
available for 1989 and 1979 was limited, further strains belonging
D159N
V196I
T163I
N172K
N189K
T187S
P227S
R140K
K207E
T46I
K310R
P55S
M260L
I213V
R140K
T187S
N189KV196I
T163I
N172K
K207E
P227SD159N
Fig. 2. HA structures: 1989 EIV outbreak. The locations of HA1 amino acid differences between vaccine and outbreak strains are indicated in red on the surface of the H3 HA
structure for A/duck/Ukraine/1/63, protein database number PDB:1MLQ (Ha et al., 2003). Amino acid differences unique to Newmarket/79 are indicated in blue. Structures
were examined using MacPyMOL and images collected for vertical (A) and top (B) views; the difference at HA1 residue 7 is not shown as the structure was solved for
bromelain-cleaved HA and lacks the transmembrane domain (Ha et al., 2003).
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Fig. 3. HA1 Phylogenetic tree showing vaccine and epidemic strains. Maximum-likelihood tree based on the nucleotide sequence encoding HA1 for 103 representative EIV
strains from major lineages and sub-lineages isolated between 1963 and 2013. Lineages, sub-lineages and major clades are indicated by bars to the right, large scale
outbreaks are indicated in boxes and strains used in this manuscript are marked by asterisks. Vaccine strains are highlighted in yellow and outbreak strains are highlighted in
green. Bootstrap values obtained from 100 replicates are indicated at major nodes, relevant amino acid substitutions are also shown at key nodes.
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to the pre-divergence, Eurasian and American/Kentucky sub-lineages
and their homologous sera were also included for comparison. For
clarity, all these strains are highlighted in the phylogenetic tree for
HA1 in Fig. 3 and an amino acid alignment is provided in Supple-
mentary data Fig. S1. HI assays were carried out using a panel of
post-infection reference antisera, raised in ferrets (Table 1). A limited
number of equine sera were also available from AHT archives, against
Newmarket/79, Sussex/89, Hong Kong/92 and Kentucky/91. Homo-
logous titres against matched virus and ferret sera ranged from 64 to
256, with the exception of Suffolk/89, which had a very low
homologous titre of 8. The homologous titres against equine sera
ranged from 8 (Newmarket/79) to 128 (Kentucky/91, Hong Kong/92).
Of the three 1989 outbreak strains, Suffolk/89 antigen gave a low
titre against most of the antisera tested, and the ferret serum was
also poor, it was therefore not selected for further work. This pattern
of reactivity is not uncommon for equine inﬂuenza H3N8 strains
(data not shown) and is typical of so-called ‘low avidity’ strains. The
remaining two outbreak strains, Yvelines/89 and Sussex/89 gave
similar results; most titres were within a two-fold difference against
all the sera tested (Table 1). Sussex/89 was selected as a UK example
of the outbreak in Europe.
Interestingly, the HI data demonstrated a one-way pattern of
cross reactivity for sera raised against viruses belonging to different
lineages. Ferret sera raised against the early pre-divergence (1979–
1981) and Kentucky strains (1990–1991) cross-reacted with most of
the strains belonging to the Eurasian lineage (Table 1). In contrast,
ferret sera raised against the more recent Eurasian viruses (1989–
1992) recognised other viruses from the same group and, to a lesser
extent, the Kentucky sublineage viruses, but showed very little
cross-reactivity against the pre-divergence strains isolated 10 years
or more earlier. The pre-divergence strains were recognised by sera
raised against similar viruses, as expected, but also by sera against
the Kentucky viruses (titres from 8 to 256). Newmarket/79 gave a
4–8 fold lower titre against these ferret sera than Fontainebleau/79,
which may have been due to the additional substitutions at posi-
tions 159 and 227 seen in this virus (Fig. 1). The pre-divergence
viruses were poorly recognised by sera raised against viruses
belonging to the Eurasian lineage, with titres ranging from o8 to
a maximum of 16. As the Eurasian viruses were recognised by sera
from all three lineages shown in Table 1, these data demonstrate
clearly that older sera did not distinguish well between different
strains and that up to date homologous sera were required to show
differences in titre of up to 32-fold between pre-divergence and
outbreak strains. The equine sera generally gave lower titres than
the ferret sera, making the data more difﬁcult to interpret. Equine
sera against the Eurasian and Kentucky viruses gave a similar
overall pattern, with both Eurasian sera giving titres of o8 against
the pre-divergence vaccine strains. The serum against Newmarket/
79 gave low titres against all the virus antigens tested; it failed to
inhibit four of the ﬁve Eurasian strains. Of all the equine sera tested,
Kentucky/91 gave the highest titres against most antigens but
consistently gave a titre of only 8 to the three pre-divergence
strains, a difference of 4–8 fold when compared against the 1989
Eurasian viruses. Taken together, the HI data indicated that anti-
genic differences were clear between the pre-divergence and
Eurasian lineages, with the greatest differences seen using the most
recent ferret sera against the Eurasian lineage.
Generation of 7:1 reassortment viruses in an H3N8 background
To analyse the antigenic effect of individual amino acid sub-
stitutions, reverse genetics was used to ﬁrst construct wild type
viruses containing HA of the vaccine strain Newmarket/79 and
outbreak strain Sussex/89 in an identical genetic background.
Segment 4 of each strain, encoding HA, was successfully rescued
as a ‘7:1 reassortant’ in the A/equine/Kentucky/02 (Kentucky/02)Ta
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reverse genetics system (Quinlivan et al., 2005). Fifteen individual
substitutions were generated by site directed mutagenesis in a
background of either Sussex/89 or Newmarket/79 HA, including
the 13 changes between the vaccine and outbreak strains plus the
additional two differences unique to Newmarket/79. Triple muta-
tions, containing the three adjacent substitutions T187S, N189K
and V196I, were made in the Newmarket/79 HA gene. These three
substitutions were in close proximity and mapped on the top
surface of HA (Fig. 2B). In the Sussex/89 background, an additional
double mutant was constructed, combining N159D and I163T.
These two changes again occurred at the top of the HA trimer
(Fig. 2); Newmarket/79 vaccine strain had both changes compared
with Sussex/89, whereas Fontainebleau/79 vaccine only differed at
163 (Fig. 1). Of the 32 resultant constructs, 31 were rescued
successfully as 7:1 reassortants in Kentucky/02. Three independent
attempts were made to rescue Sussex/89 I46T without success.
The HA sequence of each virus was determined to conﬁrm that
there were no unwanted mutations prior to antigenic analysis and
all viruses replicated to similar titres in eggs.
Antigenic characterisation of point mutants
Each virus mutant was characterised by HI assay against a panel of
post-infection ferret antisera and compared against the appropriate
recombinantWT virus (Table S2). Assays were carried out in duplicate
and repeated at least three times, geometric mean titres (GMT) were
then calculated. For ease of interpretation, fold differences were
calculated between the WT values and each mutant and are provided
in Table 2. Increases and decreases of four fold or more, generally
accepted as signiﬁcant for HI data, are highlighted in red and blue
respectively. Ferret antisera from AHT archives were used against the
two pre-divergence 1979 vaccine strains, four viruses belonging to the
Table 2
Antigenic comparison of EIV point mutants against WT reassortants by HI assay. HI assays were carried out for WT 7:1 reassortants and virus mutants, in either the
Newmarket/79 HA background (top) or the Sussex/89 HA background (bottom), against a panel of post-infection antisera raised against pre-divergent strains Newmarket/79
(New/79), Fontainebleau/79 (Fon/79); Eurasian strains Yvelines/89 (Yve/89), Sussex/89 (Sus/89), Hong Kong/92 (HK/92), Newmarket/2/93 (New/2/93); American strains
belonging to the Kentucky sub-lineage: Newmarket/1/93 (New/1/93), Kentucky/97 (Ken/97) and Florida clade 2 (FC2): Newmarket/5/03 (New/5/03). Homologous titres for
each serum against its matched parental virus are shown in bold, titres for each WT reassortant virus are highlighted in grey. Assays for each mutant were replicated a
minimum of 3 and up to 8 times then GMT values calculated and compared against the value for the appropriate WT reassortant. All titres of less o8 were assigned a value
of 1 in order to calculate GMT values. The fold difference in HI titre is shown compared to the appropriate WT virus for each point mutant, values of 4-fold or more higher are
highlighted in red, those of 4-fold or more lower are highlighted in blue.
New/79
Pre
Fon/79
Pre
Yve/89
Eur
Sus/89
Eur
HK/92
Eur
New/2/93
Eur
New/1/9
3  KY
Ken/97
KY/FC2
New/5/03
FC2
Homologous titre 128 128 256 256 256 512 256 128 256
New/79 reassortants
Wild-type GMT 279.17 49.35 1.00 1.00 1.83 1.00 1.00 16.00 8.00
T46I 2.59 1.83 2.00 1.68 3.67 1.68 2.00 1.41 2.38
P55S 0.92 1.83 2.00 1.00 2.59 1.68 4.00 1.68 2.38
R140K 1.09 1.09 1.68 1.00 3.08 1.00 1.00 1.41 1.41
D159N 0.92 4.36 2.83 1.68 0.55 1.00 90.51 11.31 2.38
T163I 0.39 0.55 1.00 1.00 0.55 1.00 1.00 0.50 0.13
N172K 0.92 1.30 2.00 1.00 0.95 1.00 1.00 2.00 1.32
T187S 0.73 1.30 1.00 1.00 0.55 1.00 1.00 1.41 1.00
N189K 0.77 1.03 32.00 32.00 8.72 20.16 1.00 0.79 0.13
V196I 0.92 1.30 1.00 1.00 0.92 1.00 1.00 1.00 1.00
T187S, N189K, V196I 0.46 0.92 32.00 64.00 2.18 22.63 1.00 2.00 0.13
K207E 0.55 1.30 1.00 1.00 0.92 1.00 1.00 1.19 1.19
I213V 0.92 1.30 1.00 1.00 0.92 1.00 1.00 1.19 1.19
P227S 1.54 3.08 13.45 1.00 10.37 1.68 5.66 2.00 3.36
M260L 0.92 1.30 1.00 1.00 0.92 1.00 1.00 1.68 1.19
I267V 1.30 1.30 1.00 1.00 0.92 1.00 1.00 1.41 1.00
K310R 0.65 1.30 1.00 1.00 1.54 1.00 1.00 1.68 1.68
Sus/89 reassortants
Wild-type GMT 5.94 57.97 141.32 190.21 26.25 172.28 23.78 95.10 13.13
S55P 1.90 1.10 1.52 1.35 1.45 1.77 0.67 0.80 0.72
K140R 0.95 1.56 2.56 1.90 2.44 2.10 1.60 1.35 1.22
N159D 2.69 0.02 0.23 0.40 0.51 0.26 0.04 0.12 0.08
N159D, I163T 3.81 0.02 0.19 0.34 0.11 0.26 0.04 0.02 0.08
T163I 2.26 1.31 0.91 0.80 1.22 1.05 1.35 1.13 0.72
K172N 1.90 1.10 1.28 1.13 1.45 1.49 0.67 0.80 0.61
S187T 1.60 1.46 1.37 0.89 0.92 0.74 1.35 0.89 0.70
K189N 0.17 1.10 0.01 0.01 0.04 0.01 1.35 1.13 0.86
I196V 1.35 1.10 0.91 0.67 1.22 1.25 0.95 0.67 0.22
E207K 3.20 1.10 1.08 1.13 1.22 1.49 0.95 0.80 0.61
V213I 0.67 1.10 1.81 1.35 1.22 1.87 0.67 1.35 0.61
S227P 0.17 0.05 0.16 0.12 0.11 0.19 0.12 0.24 0.22
L260M 1.35 1.31 1.52 1.13 2.05 1.77 1.13 1.13 0.72
V267I 2.69 1.10 1.52 1.13 2.44 2.10 1.35 0.95 1.22
R310K 1.90 0.93 0.91 0.67 1.45 1.05 0.80 0.80 0.72
Ferret Antisera
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Eurasian sub-lineage (Sussex/89, Yvelines/89, Hong Kong/92 and
Newmarket/2/93), and three members of the American sub-lineage:
one Kentucky (Newmarket/1/93), one with sequence and antigenic
similarity to both Kentucky and FC2 (Kentucky/97) and one early FC2
isolate (Newmarket/5/03). The phylogenetic relationship between
these strains is indicated in Fig. 3.
Antigenicity of Newmarket/79 point mutants
The Newmarket/79 series of mutant viruses had individual
amino acid substitutions that switched the residue to that present
in Sussex/89. The purpose was to determine whether any muta-
tions either decreased recognition by antisera against the vaccine
strains (Newmarket/79 and Fontainebleau/79) or increased recog-
nition by antisera corresponding to the Eurasian outbreak strains
(Sussex/89, Yvelines/89). The HI titres for the WT reassortant
against the panel of ferret antisera (Table 2) indicated that only
the antisera against Newmarket/79 and Fontainebleau/79 recog-
nised the Newmarket/79 WT virus well, at GMT values of 279 and
49 respectively. The antisera raised against Eurasian strains of
viruses did not recognise WT Newmarket/79, neither did the
antiserum raised against the American lineage strain Newmar-
ket/1/93, giving GMT titres below the level of sensitivity of the
assay. However, low but measurable titres of 8 and 16 were
obtained with antisera against the FC2 sub-lineage strain New-
market/5/03 and the intermediate strain Kentucky/97.
HI assays were carried out for all of the point mutants and the
fold differences between their titre and that of WT Newmarket/79
virus are shown in Table 2. The majority of the mutations had little
antigenic effect and none reduced recognition by the Newmarket/79
or Fontainebleau/79 antisera by four fold or more, suggesting that a
loss of antigenic recognition required more than one amino acid
change. This was unsurprising, as Fontainebleau/79 serum also
recognised Sussex/89 WT virus. However, three individual changes
resulted in increased titres to one or more ferret serum. In more
detail, changes at positions 46, 55, 140, 163, 172, 187, 196, 207, 213,
260, 267 and 310 had little or no effect (a difference of 2-fold or less
in titre against most sera). Of the remaining mutations, D159N was
the only change to have a pronounced effect on the reactivity to the
vaccine sera, resulting in more than a 4-fold increase in titre to
Fontainebleau/79 but having no effect on the titre against New-
market/79. This was consistent with the difference in HA1 sequence
at position 159 between the two vaccine strains (Fig. 1). Newmarket/
79/D159N also showed a marked increase in titre to antisera against
the Kentucky and Florida sub-lineage viruses Newmarket/1/93 and
Kentucky/97, increasing the titre by 90-fold and 11-fold respectively.
However, this mutation had little effect on antisera raised to the
Eurasian viruses including Sussex/89 and Newmarket/2/93, despite
all these viruses having asparagine (N) at position 159. This suggests
that this particular mutation did not make a signiﬁcant contribution
to the antigenic differences between the 1979 and 1989 viruses but
may be important for evolution of the American/Kentucky sub-
lineage. The D159N substitution occurred on the top of the HA
trimer, close to the receptor binding site but across the trimer
interface (Figs. 2 and 4). In contrast, the most obvious increase in
titre against the Eurasian antisera was observed for the single and
triple mutants containing the substitution N189K. The difference was
slightly more pronounced with the triple mutant T187S/N189K/V196I
(Table 2). However, the single substitution at 189 was sufﬁcient to
cause a marked and speciﬁc increase in recognition by all four of the
Eurasian antisera whilst having little effect on titres against American
sera. This amino acid maps to the 190 loop of the receptor-binding
site (Fig. 4). In contrast to the pattern seen for N189K, the P227S
mutation showed more complex changes in antigenicity; this sub-
stitution speciﬁcally increased recognition by two of the Eurasian
antisera, Yvelines/89 and Hong Kong/92, by more than 10 fold and
Fig. 4. Proximity of substitutions 159, 189 and 220 to the HA receptor-binding site. The locations of the three amino acid substitutions that caused the greatest antigenic
effects are indicated in red on the H3 HA structure for A/duck/Ukraine/1/63, protein database number PDB:1MLQ (Ha et al., 2003). The 130 loop, 190 helix and 220 loop
components of the receptor-binding site are indicated in blue. (A) trimeric structure, top view; (B) monomeric structure, side view.
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also increased the titre against the American antiserum to New-
market/1/93. This mutation also caused a subtle increase (three fold)
in recognition by antiserum to the vaccine strain Fontainebleau/79
but not Newmarket/79. This mutation occurs within the 220 loop
region of the receptor-binding site (Fig. 4). Taken together, these data
suggest that, like residue 159, positions 189 and 227 may also be
antigenically important for EIV.
Antigenicity of Sussex/89 point mutants
In this converse series of experiments, point mutants generated in
the Sussex/89 HA background were analysed using the same panel of
ferret antisera as that used for the Newmarket/79 mutants. The aim
was to identify single amino acid substitutions that would either
increase recognition by antisera raised against the vaccine strains
Newmarket/79 and Fontainebleau/79 or decrease recognition by the
Eurasian antisera (Sussex/89, Yvelines/89, Newmarket/2/93). All HI
assays were carried out against wild type Sussex/89 HA rescued in the
Kentucky/02 reverse genetics background as a control. The WT
Sussex/89 7:1 reassortant gave slightly lower titres overall than the
parental virus, but a similar pattern of reactivity was seen against the
Eurasian antisera (Tables 1 and 2), indicating that it was antigenically
similar and a suitable backbone to use for mutagenesis. Three of
the four Eurasian sera gave titres of more than 128, however Hong
Fig. 6. EIV epidemics: HA monomeric structures. The location of HA1 amino acid substitutions between vaccine or previous epidemic strains and outbreak isolates are
highlighted with blue boxes for large- scale outbreaks in 1979 (UK), 1989 (UK), 2003 (UK) and 2007 (Japan). The positions of antigenic sites identiﬁed for human H3N2
viruses are indicated in red, from Wiley et al. (1981), Wiley and Skehel (1987) and Wilson and Cox (1990). Antigenic site A: 122, 128, 132–146; site B: 155–160, 186–199; site
C: 50, 53–54, 91–92, 275–278; site D: 172–174, 201–207, 217–220, 242–248; site E: 62–63, 78–83. Diagrams were redrawn using Adobe Photoshop CS6.6 from structures
viewed in MacPyMOL.
Fig. 5. HA1 substitutions associated with major EIV outbreaks. Amino acid substitutions between outbreak and relevant vaccine strains, or previous epidemic strains as
appropriate, are highlighted in orange for major EIV outbreaks in 1979, 1989 (Binns et al., 1993), 2003 (Newton et al., 2006) and 2007 (Ito et al., 2008). Additional
substitutions speciﬁc to only one vaccine strain (1979 outbreak) or the less related Eurasian vaccine strain (2003 and 2007 outbreaks) are outlined by boxes. The sub-lineage
to which each outbreak belonged and the vaccine strains in use at the time are indicated: Prediv. – predivergence, FC2 – Florida clade 2, FC1 – Florida clade 1, Arg –
Argentinian, KY – Kentucky. Consensus amino acids are shown for ﬁeld strains from the early 1960s and for subsequent outbreaks, compiled from alignments of HA1
sequences available on Genbank (see Figs. S2–S5). The approximate positions of antigenic sites mapped for human H3 viruses are indicated in blue, from Wiley et al. (1981),
Wiley and Skehel (1987) and Wilson and Cox (1990), the locations of substitutions close to antigenic sites or within the same loop regions are indicated in pale blue.
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Kong/92 gave a relatively low GMT titre of 26. This was similar to the
pattern seen for the parental viruses, where the serum for Hong Kong/
92 gave a lower titre against Sussex/89 than most of the Eurasian sera
(Table 1). The Sussex/89 WT virus was not recognised by serum to
the Newmarket/79 vaccine strain (GMT value o8) but gave a
measurable titre against Fontainebleau/79, reﬂecting the antigenic
difference between the two vaccine strains.
As for the previous set of point mutations in the Newmarket/79
background, most of the mutations had little effect on recognition of
Sussex/89. All the Sussex/89 mutant viruses had low titres to the
Newmarket/79 ferret antisera, ranging from o8 up to a maximum of
16. Subtle increases in titre (around three fold) to this serum were
observed with the N159D/I163T double mutant and with E207K,
however these results indicated that no single mutationwas sufﬁcient
for the mutants to resemble the WT Newmarket/79 strain antigeni-
cally. Interestingly, neither the single or double 159 Sussex/89 mutants
were recognised by Fontainebleau/79 serum (Tables 2 and S2),
consistent with the antigenic importance of 159N for this strain.
Unlike the Newmarket/79 serum, Fontainebleau/79 serum recognised
most of the other Sussex/89 point mutants to a fairly consistent titre of
around 64 (Table 2). This suggested further that the amino acid
differences between the two vaccine strains (Fig. 1) were antigenically
signiﬁcant.
Striking results were obtained with the mutation K189N in the
Sussex/89 background, which speciﬁcally blocked recognition by
all four of the ferret antisera raised against the Eurasian viruses,
without changing the ability of the antisera raised against the
American lineages viruses to bind (Table 2). Two further Sussex/89
mutants showed obvious differences in recognition by Eurasian
sera compared to WT, with changes at 159 and 227 both reducing
HI titres by more than 4-fold against one or more serum. This
correlated to some extent with the increase in recognition seen in
mutants with the reciprocal changes D159N and P227S in the
Newmarket/79 background described above, however decreased
titres were seen against a broader selection of sera. For instance
the S227P mutation within the Sussex/89 background led to dec-
reased recognition by all the sera in the panel (Table 2). N159D had
a more speciﬁc effect, but also affected recognition by sera raised
against all 4 sub-lineages tested. Both of these mutants demon-
strated reduced recognition by American antisera raised to Ken-
tucky and FC2 viruses, although the titres for WT Sussex/89 were
relatively low to start with.
To summarise, three mutations at positions 159, 189 and 227 all
resulted in 4-fold or greater differences in HI titre, the positions of
these changes with respect to the receptor binding site is shown
in Fig. 4.
Analysis of HA1 from large-scale inﬂuenza outbreaks
To extend the analysis above, we compared the HA1 amino acid
sequence data of isolates from other known instances of vaccine
breakdown or countrywide outbreaks of equine inﬂuenza against
their respective vaccine strains or previous epidemic strains, arg-
uing that herd immunity to the previous circulating virus was also
relevant for the analysis of antigenic drift. The examples used were:
UK 1979 (previous circulating viruses and vaccine strains dated
from the early 1960s), UK 1989 described here, UK 2003 (vaccine
strains Newmarket/1/93, Newmarket/2/93, previous outbreak Sus-
sex/1989), and Japan 2007 (vaccine strains Avesta/1993, La Plata/
1993). Each outbreak is summarised in Fig. 5, which shows the sub-
lineage responsible, the relevant vaccine strains and the amino acid
differences between them, together with their location with respect
to known antigenic sites in human H3. To identify amino acid
substitutions relevant for the UK outbreak in 1979, 15 complete
equine H3N8 HA1 amino acid sequences available from the Inﬂu-
enza Virus Resource at NCBI (NCBI-IVR, Bao et al., 2008) from 1963
to 1980 were aligned (Fig. S2). Eight or more substitutions were
observed between pandemic strains from the 1960s and those from
1976 to 1979. A similar alignment was generated for the 1989
outbreak (Supplementary data, Fig. S3); alignments for the 2003
and 2007 outbreaks have been reported previously (Newton et al.,
2006; Ito et al., 2008), alignments of HA1 sequences currently
available from the NCBI-IVR are provided in Figs. S3 and S4. In most
instances, amino acid substitutions between outbreak and earlier
vaccine or epidemic strains were clear, for others the amino acid
residue at a given position was more variable between different
isolates (Figs. S2 and S3). Amino acid substitutions that may have
been important for antigenic drift in each outbreak are summarised
in Fig. 5. To determine which changes occurred within antigenic
sites, the positions of the relevant substitutions were mapped onto
the HA1 monomer, using the PDB structure of A/duck/Ukraine/63
(Fig. 6). For simplicity, antigenic sites were collated from those
described by Wiley et al. (1981), Wiley and Skehel (1987) and
Underwood et al. (1987) and are indicated in Fig. 6. All four
outbreaks involved amino acid changes in multiple locations and
within antigenic site B and at least one other. The two earlier
outbreaks (1979 and 1989) had changes in the loop regions
associated with antigenic sites A and D (Fig. 6), the two later
outbreaks (2003 and 2007) had changes in sites C or E. Several
changes were located in loop regions close to antibody binding sites
for human H3 viruses, but not actually included in these sites, such
as T46I, A272V and P289S near site C and L111I and M260L near site
D. Interestingly, 3 of the 4 outbreaks also involved changes in an
additional loop close to antigenic site C: V309I, K310R or K312N.
Amino acid substitutions at positions 48, 172, 189 and 312 were
associated with more than one outbreak. Overall, comparison of
four major outbreaks shows that at least 8 amino acid differences
were observed, affecting 2 or more of the antigenic sites deﬁned for
human H3, and several substitutions were identiﬁed that occurred
outside but close to previously deﬁned antibody binding sites.
These ﬁgures were consistent with results of the detailed reverse
genetics investigation carried out here on the UK 1989 outbreak,
which suggested that at least three amino acid substitutions
contributed to the overall antigenic difference between outbreak
and vaccine strains. The substitutions at positions 159 and 189 were
located within antigenic site B and that at position 227 occurs close
to antigenic site D. All three were close to or within the receptor-
binding site of HA (Fig. 4).
Discussion
Equine inﬂuenza viruses, like other inﬂuenza A viruses, undergo
antigenic drift as a result of amino acid substitutions in HA (Daniels
et al., 1985). Analyses of human H3N2 epidemics led to the
conclusion that two or more amino acid substitutions in two or
more antigenic sites were sufﬁcient for escape from pre-existing
immunity (Wilson and Cox, 1990). In comparison, reports suggest
that EIV does not undergo antigenic drift at the same rate as human
inﬂuenza (Murcia et al., 2011; Lewis et al., 2011). It is also not clear
howmany substitutions, where, or of what type, are required before
equine inﬂuenza vaccine breakdown is likely to occur in the ﬁeld.
Previous studies of the 1989 and 2007 outbreaks showed that
vaccines failed to protect from EIV infection when there were
between 10 and 16 amino acid differences between them (Ito et
al., 2008, Binns et al., 1993). In terms of antigenic analyses, antigenic
cartography was applied to EIV and suggested that one or two
substitutions in key sites may be sufﬁcient to cause an antigenic
‘cluster jump’ (Lewis et al., 2011). Similar results were reported for
human inﬂuenza viruses, suggesting that a very limited repertoire
of amino acid substitutions was responsible for antigenic drift
(Smith et al., 2004; Koel et al., 2013). Complications in antigenic
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analyses can arise as a result of one-way cross-reactivity in HI
assays, such as that shown here between sera raised against the
1979 vaccine strains against the emergent outbreak strains from
1989 (Table 1). Similar patterns of one-way cross reactivity have
been shown between vaccine strains belonging to the Kentucky
sublineage and outbreak viruses from the Florida sublineage
(Bryant et al., 2009, 2011). This phenomenon of sera against vaccine
strains continuing to recognise ﬁeld strains, even those known to
have caused large scale vaccine breakdown, highlights the impor-
tance of including sera raised against current strains for HI analysis.
Here we have taken an important example of EIV vaccine brea-
kdown in the ﬁeld, the 1989 incursion of the Eurasian sub-lineage
in the UK, and applied reverse genetics and site directed mutagen-
esis to facilitate an in depth study of the importance of each amino
acid substitution between vaccine and outbreak strains. The original
analyses identiﬁed 16 amino acid differences (Binns et al., 1993); by
increasing the number of sequences compared, we reduced this
number to 13 conserved differences between strains with a further
two substitutions between UK outbreak and vaccine strains. We
found that single amino acid substitutions at positions 159, 189 and
227 all affected the recognition of mutant viruses by ferret antisera.
The most striking differences were observed with substitution
K189N in the Sussex/89 background and the reciprocal change
N189K in the Newmarket/79 virus. This amino acid occurs within
antigenic site B, which underwent substitution in all four major
outbreaks of EIV described here. It is also within the 190 helix of HA,
comprising part of the receptor binding site for sialic acid for H3
viruses (Fig. 4). Site B has previously been suggested as the major
antigenic site for equine inﬂuenza viruses (Daly et al., 1996). Our
previous antigenic cartography data indicated that K189 was likely
to be important for distinguishing the Eurasian sub-lineage from
viruses with 189-D, Q or E (Lewis et al., 2011), switching of the
amino acid between uncharged, acidic and basic at position 189
thus appears to be an important factor in altering antigenic proper-
ties of EIV. Change in the residue at position 189 was also shown to
be important for antigenic drift in human and swine H3N2 viruses
(Koel et al., 2013, Ye et al., 2013, Lewis et al., 2014) and was
associated with human vaccine breakdown in Iran during the
2005–2006 inﬂuenza season (Moattari et al., 2010).
Two substitutions in the Newmarket/79 HA, D159N and P227S,
both increased recognition by antisera raised against Fontainebleau/
79 and the reciprocal changes in a Sussex/89 background reduced
recognition by Eurasian sera. Residue 227 is within the 220 loop of
the receptor-binding site of HA (Fig. 4), the substitution P227S may
therefore have had an indirect effect on the HI assay by altering
receptor-binding activity. However, the effect on HI titres shown
here was speciﬁc to a subset of the antisera used, suggesting that
this did not result in a non-speciﬁc effect on avidity. In support of
substitution at this position having antigenic potential, residue 227
was assigned to antigenic site D of human H3 by Stray and Pittman
(2012), it has previously been implicated in recognition of human
H3N2 by neutralising monoclonal antibodies (Vanlandschoot et al.,
1995) and it underwent substitution in recent human H3N2 isolates
(Bragstad et al., 2008). Alteration of the residue at position 159,
located within antigenic site B, was one of three differences bet-
ween the vaccine strains Fontainebleau/79 and Newmarket/79 and
had a profound effect on antibody recognition. 159 is located within
the 150 loop of HA, a region that is important for recognition by a
broadly neutralising monoclonal antibody against human H3 (Lee
et al., 2012). 159D found in Newmarket/79 was atypical of other
strains isolated during this period (Fig. S2), which all had 159N.
Substitution at this position may have been a component of
antigenic drift between the 1979 viruses and the original H3N8
viruses circulating in the early 1960s (Fig. 3, Fig. S2, Daniels et al.,
1985). Although we cannot pinpoint this residue as being signiﬁcant
for the UK outbreak in 1989, the substitution N159S is one of those
distinguishing the current FC1 and FC2 sub-lineages (Bryant et al.,
2009; Lewis et al., 2011) and also featured in the EIV outbreak in
Japan in 2007 (Fig. 6, Ito et al., 2008). Early representatives of the
FC1 and FC2 sub-lineages differed by only two amino acids in HA,
at positions V78A (site E) and N159S, yet showed a 4–16 fold
difference in HI titre against ferret antisera (Bryant et al., 2009). This
was despite relatively conservative substitutions, i.e. no changes in
charge or polarity, in agreement with the suggestion that the major
factor for human H3 viruses is frequency of change in a particular
residue, rather than necessarily the type of change (Stray and Pitt-
man, 2012). As substitution at 159 may be important for evolution
of more than one sub-lineage of EIV, this may play as important a
role as 189 in antigenic drift for EIV.
The antigenic characterisation of single point mutants described
above suggests that only a few amino acid changes in antigenic sites
may be needed to cause a detectable antigenic change in equine HA,
as found by Jin et al. (2005) and Koel et al. (2013) for human H3
viruses. However, epidemiological evidence from ﬁeld outbreaks of
EIV (Figs. 5 and 6) shows that sizeable outbreaks of equine inﬂuenza
have only occurred in the face of multiple amino acid changes. This is
in general agreement with data reported for human H3N2 viruses,
where epidemics and vaccine breakdown occurred in the face of
multiple changes in HA (Wiley et al., 1981; Wilson and Cox, 1990; Jin
et al., 2005). Interestingly, recent reports of antigenic drift amongst
human H3N2 viruses away from the current WHO vaccine strain
recommendations show that the drift variants have six or seven
changes affecting antigenic sites A, B and D, including substitution at
position 159 (WHO, September 2014 recommendations).
We found that at least 8 amino acid substitutions were associated
with major outbreaks, with changes in antigenic site B and at least
one other, thus the pattern did not necessarily comply with the ‘four
or more changes located in two or more antigenic sites' guideline
that arose from analyses of human epidemics (Wilson and Cox,
1990). Earlier studies concluded that at least one change in each of
the antigenic sites appeared to be required (Wiley et al., 1981, Wiley
and Skehel, 1987). For EIV epidemics, in some cases, only one change
was observed in a given site and, in several instances, amino acid
residues close to the antigenic sites showed substitutions between
vaccine and outbreak strains but had not previously been assigned to
those sites. In particular, multiple changes were located within the
loop regions associated with antigenic sites C and D (residues 48,
272, 273, 276). Multiple changes also occurred in a loop region near
the C-terminus of HA1: 309, 310, 312.
More information is required on the contribution of other inﬂu-
enza virus proteins, including NA, to protective immunity induced by
natural infection and vaccination before we can predict the inﬂuence
of antigenic drift with accuracy. The data presented here identify
some key amino acid changes that have a pronounced effect;
however, HI analysis can only detect those changes that directly or
indirectly affect binding of antibodies that block the interaction
between HA1 and sialic acid receptors. The three changes we have
highlighted all map close to the receptor binding site, as do those
mapped by Koel et al. (2013) and Lewis et al. (2014). Two of the three
changes (159, 189) involved different substitutions but at the same
locations as those highlighted for human H3N2 viruses (Koel et al.,
2013) and swine H3N2 viruses (Lewis et al., 2014). The assays
employed are unlikely to detect other relevant changes that could
alter binding by other neutralising antibodies. For instance, the
change P273L in antigenic site C was associated with the Eurasian
viruses responsible for the 1989 outbreaks and did not have an effect
on the HI titres of the antisera tested here, however this substitution
was also detected in a monoclonal antibody escape mutant of human
H3N2 (Smith et al., 1991). This type of analysis also does not consider
the importance of T-cell epitopes, which are known to exist in HA
(Babon et al., 2009; Duvvuri et al., 2010, Jameson et al., 1998).
Interestingly the region near the C-terminus of HA1, including
A. Woodward et al. / Virology 481 (2015) 187–198196
residues 309–312 highlighted above, contained an immunodominant
epitope recognised by human T helper cells isolated from people
exposed to H3 viruses (Lamb and Green, 1983). Two examples of
major EIV epidemics described here involved a vaccine strain mis-
match in this region. Detailed surveillance and careful investigation
of large-scale epidemics in the future, whether due to breakdown of
natural or vaccine-induced immunity, will aid the reﬁnement of
vaccine strain selection for EIV.
Methods
Viruses
Low passage equine inﬂuenza virus isolates from the archive at
the Animal Health Trust were inoculated into the allantoic cavities
of 10 day old embryonated hens' eggs. Eggs were incubated at 34 1C
and harvested 3 days post-infection. Virus was detected by hae-
magglutination assay (HA) using 1% chicken erythrocytes in PBS
according to standard methods (OIE, 2012). Viruses were serially
passaged until stable titres were obtained, up to a maximum of
three passages.
Plasmids
The plasmid pPolI-SapRZ, containing a human polI promoter and
delta ribozyme with SapI cloning sites, was kindly provided by
Professor Ervin Fodor, University of Oxford. The EIV reverse genetics
system for A/equine/Kentucky/02 (Quinlivan et al., 2005) was kindly
provided by Professor Peter Palese, Mount Sinai School of Medicine,
New York. Expression plasmids encoding inﬂuenza proteins PB1,
PB2, PA and NP from A/equine/Richmond/07 under the control of
the CMV IE promoter were constructed by ligating PCR products
ampliﬁed by RT-PCR from genomic viral RNA, using standard tec-
hniques. Primer sequences are available on request.
Sequencing
Viral RNAwas isolated from 140 μl allantoic ﬂuid using the QIAamp
Viral RNA mini kit (Qiagen) according to the manufacturer's instruc-
tions and eluted in 60 μl. Sequencing of segment 4, encoding HA, was
completed using overlapping PCR fragments. Brieﬂy, cDNAwas reverse
transcribed using Superscript II enzyme (Life Technologies) with
inﬂuenza A Uni-12 primer (Hoffmann et al., 2001) according to man-
ufacturer's instructions. The HA gene was ampliﬁed in the form of four
overlapping segments of approximately 500 nucleotides by PCR using
native PFU DNA polymerase (Stratagene) and equine H3 HA-speciﬁc
primers combined with M13 forward or reverse sequences as
described by Rash et al. (2014). Samples were sequenced using ABI
BigDyes Terminator v3.1 (Applied Biosystems) on an ABI PRISMs
3100 Genetic Analyser (Applied Biosystems). Nucleotide sequences
were visualised and edited using Seqman II version 5.03 (DNAstar Inc).
Reverse genetics
Viral genome segments for the equine inﬂuenza strains
A/equine/Sussex/89 and A/equine/Newmarket/79 were reverse-
transcribed from puriﬁed viral RNA using Superscript II (Invitro-
gen) and uni-12 primer, 50-AGCGAAAGCAGG-30. Segment 4,
encoding HA, was then ampliﬁed by PCR with equine inﬂuenza
HA-speciﬁc primers: ERG HA cRNA 50-CGA TGC TCT TCT GCC AGC
AAA AGC AGG GGA TAT TTC TGT C-30 and ERG HA vRNA 50-CGA
TGC TCT TCT ATT AGT AGA AAC AAG GGT GTT TTT AAC-30. PCR
products were puriﬁed, digested with SapI and ligated into
pPolISapRZ using standard techniques to generate the plasmid
pPolI-HA for both Sussex/89 and Newmarket/79. Plasmid
constructs were sequenced and the data analysed as described
above. Recombinant viruses were rescued following transfection
of 293T cells with 12 plasmids: pPolI-HA, 7 plasmids encoding the
remaining EIV genome segments from the Kentucky/02 reverse
genetics system (Quinlivan et al., 2005) and 4 expression plasmids
containing the coding sequences for PB1, PB2, PA and NP from EIV
strain A/equine/Richmond/07 ligated into pcDNA3. Plasmids were
puriﬁed from bacterial cultures using a Qiagen Maxi prep kit and
diluted to 0.5 μg/μl in water then used to transfect 293 T cells in
suspension. Brieﬂy, 10 μl Lipofectin and 100 μl Optimem were
mixed per plasmid mixture, according to manufacturer's instruc-
tions, using 1 μg each plasmid construct per transfection. Plasmids
were gently added to 1 ml 293T cells diluted to 1106 per ml in
serum-free Dulbecco's Modiﬁed Eagles Medium (DMEM) (Lonza)
then cells incubated in 6-well plates at 37 1C, 5% CO2 overnight.
Transfection supernatant was replaced with 2 ml of warmed
overlay media, consisting of serum-free DMEM with 1% Pencil-
lin/Streptomycin. 1% L/G, 0.2% Trypsin (Worthington) and 0.14%
BSA. Plates were incubated for a further 2 days, culture super-
natants were clarifed by low speed centrifugation then 100 μl
inoculated into fertile hens' eggs, as described above for growth of
EIV strains.
Haemagglutination inhibition assays
Antigenic characterisation was conducted using haemaggluti-
nation inhibition (HI) assays with ferret and equine antisera as
previously described (Bryant et al., 2009, Woodward et al., 2014).
For parental viruses, geometric mean titres (GMT) were calculated
from three HI tests for each combination. For recombinant viruses
generated by reverse genetics and mutagenesis, GMTs were
calculated from a minimum of three and maximum of eight HI
assays. Viruses were tested against post-infection antisera raised
against representative strains from the different sub-lineages of
EIV: Pre-divergence, American/Kentucky, Eurasian, Florida clade
1 and Florida clade 2.
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